Intervention Archives - ACR Meeting Abstracts

Abstract Number: 1147 • ACR Convergence 2026
Spontaneous Remission of Giant Cell Arteritis: A Case Report and Scoping Review
Grace XiuYi Nie¹ and Kun Huang² Affiliations: ¹University of British Columbia, Surrey, BC, Canada, ²University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Spontaneous remission of giant cell arteritis (GCA) is rarely reported, largely due to near-universal steroid initiation to prevent vision loss, leaving the natural history…
Abstract Number: 1616 • ACR Convergence 2026
Efficacy and Safety of Emapalumab in Adults with Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
Bruno Fautrel¹, Norbert Blank², Robert Biesen³, Melissa Elder⁴, Marco Gattorno⁵, Susan Lee⁶, Masaaki Mori⁷, Daniella Schwartz⁸, Sebastiaan Vastert⁹, Yufan Zhao¹⁰, Heather Bodenstab¹¹, Elena Burillo¹², Brian Jamieson¹¹ and Fabrizio De Benedetti¹³ Affiliations: ¹Sorbonne University - APHP, Paris, France, ²University Hospital Heidelberg, Heidelberg, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴University of Florida, Gainesville, FL, ⁵UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁶University of California San Diego, San Diego, CA, ⁷St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁸University of Pittsburgh, Pittsburgh, ⁹Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands, ¹⁰Sobi, Inc., Chadds Ford, ¹¹Sobi, Inc., Waltham, MA, ¹²Sobi, Basel, Switzerland, ¹³Bambino Gesu Children's Hospital, Rome, Rome, Italy
Background/Purpose: MAS is a life-threatening complication of Still's disease characterized by IFNg-driven hyperinflammation. Older age at MAS onset is associated with increased mortality. Emapalumab, an…
Abstract Number: 1724 • ACR Convergence 2026
Improving Post-Fracture Osteoporosis Care: Lessons from an Electronic Health Records Based Multidisciplinary Care Delivery Intervention
Alexandra Larsen¹, Andrew Kanoff¹, Joelle Koplin², Kristel Frey¹, Sarah Boise¹, Corinne Rhodes³ and Anupama Shahane³ Affiliations: ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania School of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Hip fragility fractures, sustained from falls from standing height, are diagnostic of osteoporosis and predictive of future fractures. Lifetime risk of hip fracture in…
Abstract Number: 1759 • ACR Convergence 2026
Redlining’s Enduring Impact: Linking Historic Development Policy to Missed Appointments and Health Outcomes in Rheumatology
Yusra Abu Shreikh¹, Alex Poluha*², Satvinderpal Singh², Merve Aksoy¹, Fares Saliba¹ and Katarzyna Gilek-Seiber³ Affiliations: ¹Roger Williams Medical Center, Providence, RI, ²Roger Williams Medical Center, Providence, ³Brown University, Providence
Background/Purpose: Historic redlining practices have contributed to persistent health disparities by shaping neighborhood resources, investment, and access to care [1,2]. Community hospitals in low-income regions…
Abstract Number: 1773 • ACR Convergence 2026
Assessing Barriers to Recombinant Zoster Vaccination in Immunosuppressed Adults: Baseline Data and Quality Improvement Planning For an Academic Rheumatology Clinic.
Joshua Cohen¹, Christian Volckaert¹, Scot Sternberg¹ and Tara Skorupa² Affiliations: ¹Beth Israel Deaconess Medical Center, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Immunocompromised patients are at increased risk of multiple vaccine-preventable infections, including reactivation of herpes zoster. Current guidelines recommend the recombinant Zoster vaccine (RZV) for…
Abstract Number: 1785 • ACR Convergence 2026
Impact of Multimodal Intervention on Shingrix Vaccination Rate and Herpes Zoster Incidence Among Patients on JAK or IL-6 Inhibitors
FNU Rida Ul Jannat¹, Heysel Lam² and Rupak Thapa³ Affiliations: ¹Atrium Health Wake Forest Baptist Medical Center, Winston Salem NC, Winston Salem, NC, ²Atrium Health Wake Forest Baptist, Winston Salem North Carolina, Winston Salem, ³Wake Forest University, Winston Salem North Carolina, Winston Salem, NC
Background/Purpose: Patients on JAK or IL-6 inhibitors are at increased risk for herpes zoster due to immunosuppression. Despite the 2022 ACR guidelines and CDC recommendations for a…
Abstract Number: 0081 • ACR Convergence 2026
Discovery and Preclinical Characterization of FT2109, a Differentiated Oral TNFR1 Signaling Inhibitor
Ewan Taylor¹, Ajay Maddan², Yoshiyuki Fukase³, Chun Li², Corey Wyrick⁴, Ulrich Thienel⁵ and Toufike Kanouni⁶ Affiliations: ¹Forward Therapeutics, Carlsbad, CA, ²Forward Therapeutics, Palm Beach Gardens, ³Forward Therapeutics, San Diego, CA, ⁴Forward Therapeutics, Santee, CA, ⁵Forward Therapeutics, Isabela, ⁶Forward Therapeutics, Palm Beach Gardens, FL
Background/Purpose: Biologic tumor necrosis factor (TNF) inhibitors are widely used for the treatment of inflammatory diseases. Approved biologic TNF inhibitors require parenteral administration, may be…
Abstract Number: 1795 • ACR Convergence 2026
A Pilot Trial of Computerized Action Planning for Physical Activity in Employees with Knee Symptoms
Pamela Semanik¹, Jing Song², Moath Alshahrani³, Zebadiah Boos³, Lutfiyya Mohammed⁴, Iqbal Ahamed³, Rowland Chang⁴ and Daniel Pinto⁵ Affiliations: ¹Rush University College of Nursing, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Worthington, MN, ³Marquette University, Milwaukee, WI, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Marquette University, Wauwatosa, WI
Background/Purpose: Physical activity (PA) is a critical component of symptom control and function preservation in knee osteoarthritis (OA), but few adults are active. We report…
Abstract Number: 0220 • ACR Convergence 2026
High-Intensity Immunosuppression with Autologous Stem Cell Transplantation Versus Modern Standard Care in Poor-Prognosis Diffuse Cutaneous Systemic Sclerosis: A Propensity-Matched Study
Lucas Khellaf¹, Rémi Khellaf², Pierre Pinson³, Yannick Allanore⁴, Zahir Amoura⁵, Jerome Avouac⁶, Tiphaine Goulenok⁷, Bertrand Dunogue⁸, Anuxcy Kanagaratnam⁹, Sebastien riviere¹⁰, Guillaume Buissone¹¹, Robin Dhote¹², Jean-Emmanuel kahn¹³, Olivier Lidove¹⁴, MEKINIAN Arsene¹⁵, Didier Bouscary¹⁶, Luc Mouthon⁸ and Benjamin Chaigne⁸ Affiliations: ¹Cochin university Hospital, Paris, France, ²INRIA, PreMeDICaL Team, Montpellier University, Montpellier, France;, Paris, France, ³Clinical Research Unit, Cochin Hospital, AP-HP, University Paris Cité, Paris;, Paris, France, ⁴Université Paris Cité, Paris, France, ⁵Service de médecine interne 2, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte d'Ile-de-France, Centre et Martinique, Groupement hospitalier Pitié-Salpêtrière, Institut E3M, AP-HP,, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, AP-HP, Paris, France, Paris (75014), France, ⁷Department of Internal Medicine, Bichat-Claude Bernard Hospital, AP-HP, Paris, France, ⁸Internal Medicine Department, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, Cochin Hospital, APHP, Paris Cité University, Paris, France, ⁹Internal medicine department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France;, paris, ¹⁰Internal medicine department, AP-HP Sant-Antoine Hospital, Paris;, paris, France, ¹¹Internal medicine department, AP-HP Antoine Béclère Hospital, Paris;, Paris, France, ¹²Internal medicine department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France;, Paris, France, ¹³CHU Ambroise Paré, Suresnes Cedex, ¹⁴Internal medicine and Rheumatology department, Diaconesses-Croix Saint Simon Hospital Group, Paris, France., Paris, France, ¹⁵Internal Medicine Department, Saint Antoine Hospital, APHP, Sorbonne University, Paris, France, ¹⁶Hematology department, Cochin Hospital, AP-HP, Paris., Paris, France
Background/Purpose: The 2023 EULAR update recommends high-intensity immunosuppression followed by autologous hematopoietic stem-cell transplantation (HI-IS/HSCT) for selected patients with poor-prognosis early diffuse cutaneous systemic sclerosis…
Abstract Number: 1799 • ACR Convergence 2026
Comparison of Disease-Specific Versus Non-Disease-Specific Digital Health Applications for Movement Therapy in Axial Spondyloarthritis: A Meta Analysis of Three Randomized Controlled Trials
Alp Temiz¹, Magdalena Binder², Paloma Palm von Alten Blaskowitz², Sebastian Rudolf², Vanessa Bundle², Hannah Labinsky³, Johannes Knitza⁴, Marc Schmalzing⁵, Georg Schett⁶, Patrick-Pascal Strunz⁷ and Harriet Morf² Affiliations: ¹Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 2, Rheumatology/Clinical Immunology, University Hospital Wuerzburg, Wuerzburg, Germany, Würzburg, Germany, ⁴School of Medicine, Institute for Digital Medicine, Philipps-Universität Marburg, Marburg, Germany, Marburg, Germany, ⁵University Hospital Wuerzburg, Würzburg, Germany, ⁶Department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁷Department of Internal Medicine II, Rheumatology and Clinical Immunology, University Hospital Würzburg, Wurzburg, Germany
Background/Purpose: Digital health applications (DHAs) for exercise therapy are increasingly used in axial spondyloarthritis (axSpA). Non-disease-specific DHAs for low back pain have previously been used…
Abstract Number: 0275 • ACR Convergence 2026
Pharmacodynamics of Nipocalimab, a Fully Human FcRn-Blocking Monoclonal Antibody, in Adults With Systemic Lupus Erythematosus: Results From a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (JASMINE-SLE)
Michelle Petri¹, Loqmane Seridi², Sheng Gao³, Robert Gordon⁴, Federico Zazzetti⁵, Stanley Marciniak⁶, Steven Leonardo⁷, Kathy Sivils⁸, Leonard Dragone⁹, Linda Okonkwo³, Erika Noss¹⁰, Keying Ma⁷, Ta-Ming Liu³, Fang Liu-Walsh³ and Richard Furie¹¹ Affiliations: ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johnson & Johnson, Spring House, PA, USA, Clifron Park, NY, ³Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴Johnson & Johnson, Spring House, PA, USA, Chester Springs, PA, ⁵Johnson & Johnson, Spring House, PA, USA, Horsham, ⁶Johnson & Johnson, Spring House, PA, USA, Pennyslvania, PA, ⁷Johnson & Johnson, Spring House, PA, ⁸Johnson and Johnson, Edmond, OK, ⁹Johnson & Johnson, San Francisco, CA, USA, San Francisco, CA, ¹⁰Johnson & Johnson, Spring House, PA, USA, Spring House, ¹¹Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
Background/Purpose: Autoantibodies (aAbs), predominantly of the immunoglobulin G (IgG) class, cause inflammation and tissue damage through various mechanisms, including immune activation by tissue deposition of…
Abstract Number: 1803 • ACR Convergence 2026
Improving Self-Care in Inflammatory Rheumatic Diseases Through an Adaptive Digital Training Platform: Results of the Randomized, Controlled RhPID Study
Matthias Englbrecht¹, Michael Klennert², Jana Klennert², Sonja Froschauer³, Sarah Wildenhain³, Theresia Muth⁴, Alexander Krannich⁵, Kristin Burigk⁶, Peter Bartz-Bazzanella⁷, Kirsten Karberg⁸, Georg Gauler⁹, Johannes Hornig⁹, Jacqueline Detert¹⁰, Stefanie Werner¹¹, Susanna Späthling-Mestekemper¹², Britta Welcker¹³, Wolfgang Vorbrüggen¹⁴, Martin Welcker¹⁵, Cay von der Decken¹⁶ and Stefan Kleinert¹⁷ Affiliations: ¹Healthcare Data Scientist, Grevent, Germany, ²STAR Healthcare Management GmbH, Köln, Germany, ³BDRh Service GmbH, Grünwald, Germany, ⁴BDRh Service GmbH, Grünwald, Bayern, Germany, ⁵BioStats GmbH, Nauen, Germany, ⁶Praxisgemeinschaft Rheumatologie-Nephrologie (PGRN), Erlangen, Germany, ⁷Rhein-Maas Klinikum, Würselen, Germany, ⁸Rheumatologische Versorgungszentrum Steglitz MVZ GmbH, Berlin, Germany, ⁹Rheumatologische Schwerpunktpraxis Osnabrück, Osnabrück, Germany, ¹⁰Rheumatologisch-immunologische Arztpraxis Templin, Templin, Germany, ¹¹Rheumatologie, Immunologie, Osteologie (RHIO), Düsseldorf, Germany, ¹²Rheumapraxis München, München, Germany, ¹³Britta Welcker Health Coaching, Planegg, Germany, ¹⁴Verein zur Förderung der Rheumatologie e.V. Würselen, Würselen, Germany, ¹⁵Privatpraxis Dr. Martin Welcker, Planegg, Germany, ¹⁶Medizinisches Versorgungszentrum, Stolberg, Germany, ¹⁷PGRN.de, Erlangen, Germany
Background/Purpose: Self-care is a proactive strategy that might also modify outcomes in inflammatory rheumatic diseases (IRDs), yet structured support is rarely available in routine care.…
Abstract Number: 0456 • ACR Convergence 2026
LFD-200, an Antibody Drug Conjugate That Selectively Delivers a Glucocorticoid to Immune Cells, has Anti-Inflammatory Activity and was Well Tolerated Without Systemic Side Effects in an Ongoing Phase 1 Study
Rex Williams¹, Ofer M. Gonen², Geoffrey Kuesters¹, Emily Sansevere¹, Chris Burnett¹, Margaret Smith¹, Jay Rothstein¹ and Matthew McClure¹ Affiliations: ¹Lifordi Immunotherapeutics, Burlington, MA, ²Nucleus Network, Melbourne, Australia
Background/Purpose: LFD-200 is a novel antibody drug conjugate (ADC) containing a monoclonal antibody (mAb) that binds to an immune cell surface protein, V-domain immunoglobulin suppressor…
Abstract Number: 2224 • ACR Convergence 2026
Safety and Efficacy of Enpatoran in Lupus: Results Up To 109 Weeks of the Phase II WILLOW Long-Term Extension Study
Eric Morand¹, Ruth Fernandez-Ruiz², Joseph Okebe³, Hans Gühring⁴, Yidi Wang⁵ and Jorge Sanchez-Guerrero⁶ Affiliations: ¹Centre for Inflammatory Disease, Monash University, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ²EMD Serono, Billerica, MA, ³Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, ⁴Merck Healthcare KGaA, Darmstadt, Germany, ⁵Merck Serono Co., Ltd, an affiliate of Merck KGaA, Darmstadt, Germany, Beijing, China (People's Republic), ⁶Mount Sinai Hospital and University Health Network, University of Toronto (at time of study), Toronto, ON, Canada
Background/Purpose: Novel lupus therapies that provide sustained clinical responses and long-term tolerability are needed. Enpatoran is an oral, selective, potent, and reversible dual inhibitor of…
Abstract Number: 0550 • ACR Convergence 2026
Evaluation of a Health Equity Check-In Tool on an Inpatient Pediatric Rheumatology/Nephrology Team
Sophia DeKlotz, Elizabeth Blecharczyk, Shannon Chan, Shamita Punjabi, Sarah Hilgenberg and Hannah Kohrman Affiliations: Stanford Pediatrics, Palo Alto, CA
Background/Purpose: Inequities have a profound impact on child health within Pediatric Rheumatology and Nephrology, with children from marginalized racial, ethnic, and socioeconomic backgrounds experiencing worse…

Abstracts tagged "Intervention"